NASDAQ$VCEL

Vericel Corporation · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Vericel reported financial results for Q4 and full year 2021 and provided full-year 2022 financial guidance.

Vericel reported a 5% increase in total net revenue for the fourth quarter of 2021, reaching $47.6 million. Net income was $4.5 million, or $0.09 per share, and non-GAAP adjusted EBITDA was $12.8 million.

  • Total net revenue of $47.6 million, compared to $45.2 million in the fourth quarter of 2020.
  • MACI® net revenue of $37.3 million, Epicel® net revenue of $9.7 million, and NexoBrid® revenue of $0.5 million related to the U.S. Biomedical Advanced Research and Development Authority (BARDA) procurement for emergency response preparedness
  • Net income of $4.5 million, or $0.09 per share, compared to $12.2 million, or $0.25 per share, in the fourth quarter of 2020.
  • Non-GAAP adjusted EBITDA of $12.8 million, compared to $16.0 million in the fourth quarter of 2020.

Headline financials

Total Revenue

$47.6M

Previous: $45.2M+5.2%
EPS (adj)

$0.09

Previous: $0.25-64.0%
Gross Margin

72.0%

Previous: 74.0%-2.7%
Adjusted EBITDA

$12.8M

Previous: $16M-20.2%
Capital Expenditures

$991K

Previous: $1.07M-7.4%
Free Cash Flow

$9.56M

Previous: $10.3M-6.9%
Net Income

$4.5M

Previous: $12.2M-63.1%
Operating Income

$4.14M

Previous: $12.3M-66.3%
Gross Profit

$34M

Previous: $33.6M+1.1%
Cash & Equivalents

$68.3M

Previous: $33.6M+103.2%
Total Assets

$244M

Previous: $206M+18.5%
Stock-Based Comp

$7.84M

Previous: $3.02M+159.3%

Revenue & EPS history

Vericel · Revenue · Quarterly

$47.6M

Q4 2021+5.2%vs Q4 2020
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

Vericel · $47.5M total across 3 segments · Q4 2021

  • MACI
    $37.3M+7.5%
  • Epicel
    $9.7M+1.0%
  • NexoBrid
    $500K-50.0%

Forward guidance

Total net revenue for 2022 expected to be in the range of $178 to $189 million. MACI revenue expected to be in the range of $132 to $141 million. Epicel revenue expected to be in the range of $45.5 to $47.5 million. Gross margin expected to be approximately 70%. Adjusted EBITDA margin expected to be approximately 21%.

Tailwinds

  • Total net revenue for 2022 expected to be in the range of $178 to $189 million.
  • MACI revenue expected to be in the range of $132 to $141 million.
  • Epicel revenue expected to be in the range of $45.5 to $47.5 million.
  • Gross margin expected to be approximately 70%.
  • Adjusted EBITDA margin expected to be approximately 21%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+1.4%

Avg return

Earnings day

+2.8%

Avg return

5 days after

+2.2%

Avg return

30 days after

47%

30 / 64 earnings

Positive

+48.1%

Q3 2018

Best reaction

-30.0%

Q2 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.6%-10.4%-1.4%
Q4 2025+1.7%-7.3%-20.9%
Q3 2025+4.6%+10.3%-2.6%
Q1 2025+3.2%+7.8%+7.0%
Q4 2024-6.1%-3.2%-15.8%
Q3 2024+12.4%+16.3%+17.3%
Q2 2024-5.7%-7.5%+2.2%
Q1 2024-1.8%-2.0%-10.4%
Q4 2023-6.5%-7.0%+8.8%
Q3 2023-11.2%-7.0%-7.3%
Q2 2023-8.9%-9.2%-3.5%
Q1 2023+0.5%+2.8%+6.5%
Q4 2022+6.9%+6.6%+1.6%
Q3 2022-2.8%+0.2%-0.3%
Q2 2022-4.3%-6.2%-28.7%
Q1 2022-9.1%-18.9%-13.1%
Q4 2021+21.9%+26.4%+11.2%
Q3 2021-2.7%-3.0%-10.6%
Q2 2021-2.1%-4.5%+9.0%
Q1 2021-10.2%-15.9%-5.8%
Q4 2020+0.4%+1.7%+9.0%
Q3 2020+6.0%+17.7%+18.5%
Q2 2020-9.8%-5.0%-5.5%
Q1 2020+5.6%+8.3%+3.9%
Q4 2019-20.4%-18.3%-46.9%
Q3 2019+15.3%+15.7%+12.9%
Q2 2019+2.4%+1.9%-8.3%
Q1 2019-2.5%-3.6%-16.8%
Q4 2018-7.4%-3.5%-13.6%
Q3 2018+48.1%+39.6%+53.3%
Q2 2018+25.6%+27.1%+36.5%
Q1 2018+6.0%+5.6%+0.4%
Q4 2017+40.1%+38.3%+33.5%
Q3 2017-7.0%-5.8%+14.0%
Q2 2017+11.7%+21.7%+48.3%
Q1 2017+0.0%+3.9%+5.9%
Q4 2016-1.7%+0.0%-6.9%
Q3 2016-2.3%+4.7%+9.3%
Q2 2016-5.5%-7.7%-5.5%
Q1 2016+11.5%
Q4 2015+4.8%
Q3 2015-9.7%
Q2 2015+4.3%
Q1 2015-2.5%
Q4 2014+2.9%
Q3 2014+3.6%
Q2 2014-0.3%
Q1 2014+0.5%
Q4 2013-12.7%
Q3 2013-2.2%
Q2 2013-30.0%
Q1 2013+0.0%
Q4 2012-6.3%
Q3 2012-4.0%
Q2 2012-6.5%
Q1 2012-0.8%
Q4 2011+1.0%
Q3 2011+3.1%
Q2 2011+8.3%
Q1 2011+4.7%
Q4 2009+4.7%
Q3 2010+35.3%
Q2 2010+0.0%
Q1 2010+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro